Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for ...

After the gutting of the Department of Health and Human Services, fears mount about the future direction of the FDA—with ...

AI is enabling the development of a next generation of drugs that can more precisely target cancer cells while sparing ...

The number of employees laid off dropped year over year during the first quarter. BioSpace recaps the five largest layoffs, ...

Health and Human Services employees aren’t the only ones out of work. Thousands of private-sector biopharma professionals ...

As the biopharma industry grapples with the uncertain macro environment brought on by the new administration, CEOs, ...

Experts express concern that last week's unprecedented FDA layoffs will trigger a little-known mechanism that could result in ...

According to analysts at Jefferies, legislation such as the newly proposed bills that aim to streamline regulatory processes ...

Novartis plans to build seven new facilities in the U.S., touting the creation of up to 1,000 new jobs at the company. The ...

Analysts at William Blair expect drug developers will continue to perform “at least some animal testing” on their ...

Biotech companies are already seeing regulatory delays and plenty of uncertainty after around 3,500 FDA employees were cut by ...

The threat of tariffs has put the pharma industry through the wringer this week. On Wednesday, a week after instituting widespread tariffs and a day after promising that “major” tariffs were headed ...